Literature DB >> 19833632

Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.

Damien R Ashby1, Daniel P Gale, Mark Busbridge, Kevin G Murphy, Neill D Duncan, Tom D Cairns, David H Taube, Stephen R Bloom, Frederick W K Tam, Richard Chapman, Patrick H Maxwell, Peter Choi.   

Abstract

Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow-hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833632      PMCID: PMC2833083          DOI: 10.3324/haematol.2009.013136

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

Review 1.  Molecular control of iron transport.

Authors:  Tomas Ganz
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

2.  Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera.

Authors:  Orly Weizer-Stern; Konstantin Adamsky; Ninette Amariglio; Carina Levin; Ariel Koren; William Breuer; Eliezer Rachmilewitz; Laura Breda; Stefano Rivella; Z Ioav Cabantchik; Gideon Rechavi
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

3.  Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.

Authors:  Lénaïck Détivaud; Elizabeta Nemeth; Karim Boudjema; Bruno Turlin; Marie-Bérengère Troadec; Patricia Leroyer; Martine Ropert; Sylvie Jacquelinet; Brice Courselaud; Tomas Ganz; Pierre Brissot; Olivier Loréal
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

4.  Suppression of hepcidin during anemia requires erythropoietic activity.

Authors:  Mihwa Pak; Miguel A Lopez; Victroia Gabayan; Tomas Ganz; Seth Rivera
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

5.  Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.

Authors:  Erwin Kemna; Peter Pickkers; Elizabeta Nemeth; Hans van der Hoeven; Dorine Swinkels
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

6.  An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2007-02-21       Impact factor: 4.200

7.  Regulation of hepcidin: insights from biochemical analyses on human serum samples.

Authors:  Erwin H J M Kemna; April E R Kartikasari; Lambertus J H van Tits; Peter Pickkers; Harold Tjalsma; Dorine W Swinkels
Journal:  Blood Cells Mol Dis       Date:  2007-11-26       Impact factor: 3.039

8.  Immunoassay for human serum hepcidin.

Authors:  Tomas Ganz; Gordana Olbina; Domenico Girelli; Elizabeta Nemeth; Mark Westerman
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

9.  High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.

Authors:  Toshihiko Tanno; Natarajan V Bhanu; Patricia A Oneal; Sung-Ho Goh; Pamela Staker; Y Terry Lee; John W Moroney; Christopher H Reed; Naomi L C Luban; Rui-Hong Wang; Thomas E Eling; Richard Childs; Tomas Ganz; Susan F Leitman; Suthat Fucharoen; Jeffery L Miller
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

10.  Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis.

Authors:  M Vokurka; J Krijt; K Sulc; E Necas
Journal:  Physiol Res       Date:  2006       Impact factor: 1.881

View more
  68 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  The evolving science of detection of 'blood doping'.

Authors:  Carsten Lundby; Paul Robach; Bengt Saltin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

4.  Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys.

Authors:  Wojciech Krzyzanski; Jim J Xiao; Barbra Sasu; Beth Hinkle; Juan Jose Perez-Ruixo
Journal:  AAPS J       Date:  2016-02-25       Impact factor: 4.009

5.  Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers.

Authors:  Fabrice Lainé; Bruno Laviolle; Martine Ropert; Guillaume Bouguen; Jeff Morcet; Catherine Hamon; Catherine Massart; Mark Westermann; Yves Deugnier; Olivier Loréal
Journal:  Eur J Appl Physiol       Date:  2011-08-05       Impact factor: 3.078

6.  Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.

Authors:  Jason S Troutt; Anthony M Butterfield; Robert J Konrad
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

7.  Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.

Authors:  Lavinia Oltiţa Brătescu; Liliana Bârsan; Liliana Gârneaţă; Ana Stanciu; Mariana Lipan; Simona Hildegard Stancu; Gabriel Mircescu
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

Review 8.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

9.  Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors.

Authors:  Melanie Volke; Daniel P Gale; Ulrike Maegdefrau; Gunnar Schley; Bernd Klanke; Anja-Katrin Bosserhoff; Patrick H Maxwell; Kai-Uwe Eckardt; Christina Warnecke
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

10.  Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.

Authors:  Elizabeta Nemeth
Journal:  Adv Hematol       Date:  2009-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.